This article provides a brief overview of targeted cancer therapy and discusses certain challenges to their development, as they relate to the Phase I clinical development setting.
In addition, a unique concept developed by Scimega Research, called the Reverse Feasibility™ Program, is explained to demonstrate opportunities that exist to support the efforts of both industry and clinicians.
What are your thoughts on this topic? Join the discussion in the Optimizing Oncology Clinical Research group on LinkedIn.
Sign up to